Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications.
New blood-based epigenetic tests can detect cancer and track remaining disease without biopsies, opening doors to easier monitoring and earlier intervention.
This review in NPJ Precision Oncology covers the technological evolution and clinical applications of cfMeDIP-seq, an epigenetic liquid biopsy platform that interrogates DNA methylation in cell-free DNA. The technology enables cancer detection, minimal residual disease monitoring, and tissue-of-origin identification without tumor tissue.
What the study was
- Study design
- Review
- Population
- Cancer patients broadly; review covers multiple tumor types
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- NPJ Precision Oncology
Why it surfaced
High-quality review of an emerging epigenetic liquid biopsy platform in a top precision oncology journal; relevant to early detection and MRD watchlist topics.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.